152 related articles for article (PubMed ID: 10900359)
1. Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta.
Ozenci V; Kouwenhoven M; Teleshova N; Pashenkov M; Fredrikson S; Link H
J Neuroimmunol; 2000 Aug; 108(1-2):236-43. PubMed ID: 10900359
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients.
Galboiz Y; Shapiro S; Lahat N; Rawashdeh H; Miller A
Ann Neurol; 2001 Oct; 50(4):443-51. PubMed ID: 11601495
[TBL] [Abstract][Full Text] [Related]
3. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients.
Bernal F; Elias B; Hartung HP; Kieseier BC
Mult Scler; 2009 Jun; 15(6):721-7. PubMed ID: 19383643
[TBL] [Abstract][Full Text] [Related]
4. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
Navikas V; Matusevicius D; Söderström M; Pirskanen R; Fredrikson S; Link H
Clin Neuropharmacol; 1998; 21(4):236-44. PubMed ID: 9704165
[TBL] [Abstract][Full Text] [Related]
5. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis.
Link J
Acta Neurol Scand Suppl; 1994; 158():1-58. PubMed ID: 7732782
[TBL] [Abstract][Full Text] [Related]
6. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment.
Ozenci V; Kouwenhoven M; Huang YM; Kivisäkk P; Link H
Clin Exp Immunol; 2000 Apr; 120(1):147-53. PubMed ID: 10759776
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase and cytokine profiles in monocytes over the course of stroke.
Kouwenhoven M; Carlström C; Ozenci V; Link H
J Clin Immunol; 2001 Sep; 21(5):365-75. PubMed ID: 11720009
[TBL] [Abstract][Full Text] [Related]
8. Multiple sclerosis: elevated expression of matrix metalloproteinases in blood monocytes.
Kouwenhoven M; Ozenci V; Gomes A; Yarilin D; Giedraitis V; Press R; Link H
J Autoimmun; 2001 Jun; 16(4):463-70. PubMed ID: 11437495
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.
Gilli F; Bertolotto A; Sala A; Hoffmann F; Capobianco M; Malucchi S; Glass T; Kappos L; Lindberg RL; Leppert D
Brain; 2004 Feb; 127(Pt 2):259-68. PubMed ID: 14607790
[TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis: levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment.
Ozenci V; Kouwenhoven M; Huang YM; Xiao B; Kivisäkk P; Fredrikson S; Link H
Scand J Immunol; 1999 May; 49(5):554-61. PubMed ID: 10320650
[TBL] [Abstract][Full Text] [Related]
11. Metalloproteinases and their tissue inhibitors in multiple sclerosis.
Ozenci V; Rinaldi L; Teleshova N; Matusevicius D; Kivisäkk P; Kouwenhoven M; Link H
J Autoimmun; 1999 Jun; 12(4):297-303. PubMed ID: 10330301
[TBL] [Abstract][Full Text] [Related]
12. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1.
Feng X; Petraglia AL; Chen M; Byskosh PV; Boos MD; Reder AT
J Neuroimmunol; 2002 Aug; 129(1-2):205-15. PubMed ID: 12161037
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor-beta 1 suppresses autoantigen-induced expression of pro-inflammatory cytokines but not of interleukin-10 in multiple sclerosis and myasthenia gravis.
Link J; He B; Navikas V; Palasik W; Fredrikson S; Söderström M; Link H
J Neuroimmunol; 1995 Apr; 58(1):21-35. PubMed ID: 7537278
[TBL] [Abstract][Full Text] [Related]
14. Modulation of monocytes matrix metalloproteinase-2, MT1-MMP and TIMP-2 by interferon-gamma and -beta: implications to multiple sclerosis.
Galboiz Y; Shapiro S; Lahat N; Miller A
J Neuroimmunol; 2002 Oct; 131(1-2):191-200. PubMed ID: 12458052
[TBL] [Abstract][Full Text] [Related]
15. Interferon beta-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis.
Byskosh PV; Reder AT
Mult Scler; 1996 Apr; 1(5):262-9. PubMed ID: 9345428
[TBL] [Abstract][Full Text] [Related]
16. Monocyte-derived dendritic cells express and secrete matrix-degrading metalloproteinases and their inhibitors and are imbalanced in multiple sclerosis.
Kouwenhoven M; Ozenci V; Tjernlund A; Pashenkov M; Homman M; Press R; Link H
J Neuroimmunol; 2002 May; 126(1-2):161-71. PubMed ID: 12020967
[TBL] [Abstract][Full Text] [Related]
17. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.
Alexander JS; Harris MK; Wells SR; Mills G; Chalamidas K; Ganta VC; McGee J; Jennings MH; Gonzalez-Toledo E; Minagar A
Mult Scler; 2010 Jul; 16(7):801-9. PubMed ID: 20621951
[TBL] [Abstract][Full Text] [Related]
18. IFN-beta 1b treatment of relapsing multiple sclerosis has no effect on CD3-induced inflammatory or counterregulatory anti-inflammatory cytokine secretion ex vivo after nine months.
Brod SA; Nelson LD; Khan M; Wolinsky JS
Int J Neurosci; 1997 Jun; 90(1-2):135-44. PubMed ID: 9285295
[TBL] [Abstract][Full Text] [Related]
19. Increased expression ratio of matrix metalloproteinase-9 (MMP9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) RNA levels in Iranian multiple sclerosis patients.
Nazdik MK; Taheri M; Sajjadi E; Arsang-Jang S; Koohpar ZK; Inoko H; Sayad A
Hum Antibodies; 2016; 24(3-4):65-70. PubMed ID: 27689613
[TBL] [Abstract][Full Text] [Related]
20. Expression of interleukin-1 beta, tumor necrosis factor alpha, interleukins-6, -10 and -4, and metalloproteases by freshly isolated mononuclear cells from early never-treated and non-acute treated rheumatoid arthritis patients.
Vázquez-Del Mercado M; Delgado-Rizo V; Muñoz-Valle JF; Orozco-Alcalá J; Volk HD; Armendáriz-Borunda J
Clin Exp Rheumatol; 1999; 17(5):575-83. PubMed ID: 10544841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
